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ABSTRACT 
 
Background: An association between celiac disease and renal diseases has been suggested, but the 
results are controversial.  
Aims: To investigate the prevalence of celiac disease autoimmunity among individuals undergoing 
renal biopsies and to evaluate whether co-existent celiac autoimmunity influences the clinical 
outcome of the renal disease. 
Methods: The prevalence of celiac autoimmunity (previous diagnosis of celiac disease or positive 
tissue transglutaminase antibodies) was determined in 827 consecutive patients undergoing kidney 
biopsies due to clinical indications. Up to 15 years’ follow-up data on kidney function and co-
morbidities were obtained. 
Results: Celiac autoimmunity was found in 45 (5.4%) patients. Among the IgA nephropathy patients, 
8.2% of had celiac autoimmunity. At the time of kidney biopsy and after a median follow-up of 5 to 
6 years, renal function measured by estimated glomerular filtration rate (eGFR) was inferior in IgA 
nephropathy patients with celiac autoimmunity compared to those without it (P=0.048 and P=0.022, 
respectively).  
Conclusion: The prevalence of celiac autoimmunity seems to be high in patients undergoing renal 
biopsies, especially in patients with IgA nephropathy. Such autoimmunity may be associated with 
worse renal function in IgA nephropathy. Hence the co-existence of celiac disease should be taken 
into consideration when treating patients with renal diseases.  
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1. Introduction  
 
Celiac disease develops from an autoimmune response to dietary gluten, the storage protein of 
wheat, rye and barley, and it occurs in about 1-2% of the Western population [1]. Typically, the 
disease is characterized by diarrhea and malabsorption but nowadays many patients have only a mild 
constellation of symptoms, which often manifest widespread outside the gastrointestinal tract (eg. 
dermatitis herpetiformis, infertility, neurological problems, osteoporotic fractures, hepatitis and liver 
failure) [2,3]. Furthermore, in the majority of cases the condition may be clinically silent and found 
only by active case-finding in celiac disease risk groups such as patients with type 1 diabetes mellitus 
and other autoimmune disorders [4]. The heterogeneous clinical picture constitutes a challenge to 
physicians, and despite the increased awareness of celiac disease the diagnostic delay often exceeds 
10 years and even 75-90% of the patients remain undiagnosed [5,6]. The burden of untreated celiac 
disease can be remarkable for patients and health care system, and additionally predispose patients to 
different kinds of complications of celiac disease [4,6]. Hence early diagnosis and life-long gluten 
free diet as a valid treatment are urgently needed [7]. 
Autoantibodies specific for the enzyme tissue transglutaminase are currently a hallmark of celiac 
disease. Serological tests are widely used to facilitate preselection of patients for diagnostic 
endoscopy and small bowel biopsy [3]. An association between celiac disease and renal diseases has 
been suggested using these autoantibodies [8,9]. According to previous studies celiac disease is 
overrepresented in patients with IgA nephropathy even though the results have remained 
contradictory [10-12]. Swedish epidemiologic data showed an increased risk of chronic and end-stage 
renal diseases among patients with celiac disease [8]. Interestingly, certain cases with IgA 
nephropathy might improve on a low antigenic diet lacking gluten [13,14]. Despite suggested 
associations between celiac disease and kidney diseases, current clinical guidelines do not consider 
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patients with renal conditions to be at high risk for celiac disease and no systematic screening is 
recommended [2].  
The aim of this study was to investigate the prevalence of celiac disease autoimmunity among 
patients undergoing kidney biopsies and to determine whether co-existent celiac autoimmunity has 
any effect on the clinical outcome of the renal disease. 
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2. Subjects and methods 
 
2.1. Patients and study design  
 
 The study cohort consisted of 827 individual patients to whom a kidney biopsy was performed 
consecutively at Tampere University Hospital, Finland, during the years 2000-2012. The kidney 
biopsy specimens were taken and processed by standard methods, as earlier described [15]. The 
referral letters and the pathology reports of the kidney samples were re-read and structurally 
categorized. Firstly, the kidney biopsy indications were classified to seven groups as follows: diffuse 
nephritic syndrome (hematuria and the daily urinary excretion of more than 1.5 g of protein), focal 
nephritic syndrome (hematuria and the daily urinary excretion of less than 1.5 g of protein), nephrotic 
syndrome (the daily urinary excretion of more than 3.5 g of protein without hematuria), proteinuria 
(the daily urinary excretion of protein 0.3- 3.5 g without hematuria), hematuria (the daily urinary 
excretion of protein less than 0.3 g), renal insufficiency (elevated creatinine levels) or any other 
indication. Secondly, the four groups were formed based on the histopathological findings of the 
kidney biopsy specimens: glomerular diseases, tubulointerstitial diseases, vascular diseases, and other 
findings. Blood samples were taken at the day of kidney biopsy, serum was separated by 
centrifugation at 1500xg for 10 min and subsequently frozen and stored at –80 C until analyzed for 
IgA-class tissue transglutaminase antibodies (tTGA). The patients with available blood samples were 
included in the current study. The clinical histories of patients were collected systematically from the 
medical records of Tampere University Hospital during 2014-2015. The study population was divided 
into two groups according to presence or absence of celiac disease autoimmunity, which was defined 
as having previous celiac disease diagnosis or positive tTGA. 
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2.2. Serological tests 
 
Serum IgA-class tTGA were investigated by enzyme-linked immunosorbent assay (ELISA) 
according manufacturers’ instruction (Celikey®, Phadia, GmbH, Freiburg, Germany). All analyses 
were carried out blind to the knowledge of the clinical information. Values higher than 3.0 U were 
regarded as positive [16,17]. 
 
2.3. Clinical data 
 
The medical files were systematically analysed by the same investigator. Data on previous 
diagnoses of celiac disease as well as type 1 and 2 diabetes mellitus, hypertension and hyperlipidemia 
were collected. Weight and height values were recorded at the time of kidney biopsy and body mass 
indexes (BMIs) calculated as weight/height2 (kg/m2). Plasma creatinine, daily urinary protein 
excretion and data of hematuria were gathered from medical records at the time of biopsy and at the 
latest follow-up. The values of urine dipstick test showing hematuria were dichotomized as negative 
(values 0 or +) or positive (values ++ or +++). Estimated glomerular filtration rate (eGFR) was 
defined using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation [18]. 
Annual change of eGFR was determined by dividing the differences between baseline and end eGFR 
values by number of follow-up years. Furthermore, data on need for renal dialysis or renal transplant 
as well as mortality during the follow-up period was recorded. 
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2.4. Statistical methods 
 
Quantitative data was expressed as medians and ranges. Statistical differences were evaluated by 
using Mann-Whitney test, Chi-square test, independent t-test or Fisher's test. A P value less than 0.05 
was considered statistically significant. All statistical testing was performed using SPSS version 17.0 
(SPSS Inc., Chicago, IL, USA). 
 
2.5. Ethical consideration 
 
The study protocol was approved by the Ethical Committee of Tampere University Hospital. All 
subjects gave written informed consent at the time of kidney biopsy.  
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3. Results 
 
Altogether 827 patients who underwent renal biopsies during 2000-2012, were enrolled in the 
analyses (38% female, median age 59 years, range 16-85 years). Forty-five (5.4%) out of the 827 
patients were found to have celiac disease autoimmunity; nine (1.1%) had previously diagnosed celiac 
disease (56% female, median age 59 years, range 35-76 years) and additional 36 subjects had elevated 
serum tTGA level (31% female, median age 60 years, range 21-83 years). Twelve tTGA-positive 
subjects had antibody values higher than 2x upper normal limit (range 7.6-87.0 U), 24 had lower 
positive values (range 3.1-5.4 U). The indications for kidney biopsies and the biopsy findings were 
not significantly different between patients with or without celiac disease autoimmunity (P=0.328 
and P=0.580, respectively; Tables 1 and 2). Glomerular disease was the most common finding in both 
groups. 
When analyzing the available data of patients having the most common glomerulonephritis, IgA 
nephropathy, separately, the prevalence of celiac disease autoimmunity was 8.2% among them (12 
out of 147). There were no differences in age or gender distribution between the IgA nephropathy 
patients with or without celiac disease autoimmunity (Table 3). In comparison of the prevalence of 
co-morbidities, there was a trend showing that patients with celiac disease autoimmunity had higher 
prevalence of hypertension than those without autoimmunity (11 [92%] out of 12 vs. 83 [62%] out 
of 134, P=0.056). However, patients in the celiac disease autoimmunity group did not suffer 
significantly more from hyperlipidemia or type 2 diabetes (4 [33%] out of 12 vs. 48 [36%] out of 134, 
P=1.000, and 3 [25%] out of 12 vs. 18 [13%] out of 135, P=0.380, respectively). None of the patients 
in the present series had type 1 diabetes. At the time of the kidney biopsy, the renal function was 
inferior in IgA nephropathy patients with celiac disease autoimmunity; creatinine levels were higher 
and eGFR lower among this patient group (Table 3). After a median follow-up period of 5 to 6 years 
the same trend still existed showing the difference in renal function between groups divided according 
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to celiac disease autoimmunity. Nevertheless, the annual change of eGFR and a need for dialysis or 
transplantation during the follow-up period were not different between the groups (Table 3). Twenty-
five percent out of the IgA nephropathy patients with celiac disease autoimmunity died during the 
follow-up, while the prognosis seemed to be slightly better in the group without celiac autoimmunity 
(10% died, Table 3). Still, this difference did not reach statistical significance. The causes of death 
were not known. 
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4. Discussion 
 
This study shows that 5.4% of patients undergoing kidney biopsies have evidence of celiac disease 
autoimmunity.  Such prevalence is approximately three times higher than percentages achieved in 
serologic celiac disease screening studies in general population [5,19]. Even though the prevalence 
of clinically diagnosed celiac disease in this patient cohort was slightly higher (1.1%), than that in 
the Finnish general population (0.7%) [20], the majority of patients with celiac disease autoimmunity 
had remained undiagnosed before the current study. This finding is consistent with the current 
knowledge that the association between celiac disease and renal disorders often stays unrecognised 
by clinicians. Current clinical guidelines do not recommend systematic screening of celiac disease 
among kidney disease patients [2]. However our findings support this kind of screening. 
The current study also confirmed the association between celiac disease and IgA nephropathy, as 
almost 8% of the IgA nephropathy patients were found to have celiac disease autoimmunity. Similar 
positive association has been demonstrated also in our previous cohort of 223 IgA nephropathy 
patients diagnosed in the 1980’s [10]. In addition, a large Swedish epidemiologic study with 27 000 
celiac disease patients showed that celiac disease patients suffer a 3-fold increased risk of future IgA 
nephropathy [11]. Still, despite such large celiac disease patient cohort, the number of patients found 
to have IgA nephropathy was small and eventually only seven cases had these two co-existent 
disorders [11]. There are also some previous studies showing negative associations between celiac 
disease and IgA nephropathy [12,21]. The reason for the contradictory findings might be explained 
by small study groups or the use of immunosuppressive drugs which can lead to negative results in 
serological screening. 
It is well known that celiac disease is detected even among one tenth of the patients with type 1 
diabetes [3]. A previous epidemiological study showed an increased risk for end-stage renal disease 
among patients with celiac disease, and the most common underlying renal disorder causing end-
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stage renal disease among celiac disease patients was diabetic nephropathy [22]. The reason for type 
1 diabetes being underrepresented in the current study might be that the diagnosis of diabetic 
nephropathy is usually done clinically and no biopsies are needed [23]. Hence patients suffering from 
type 1 diabetes and renal problems would not have been included in the study cohort of patients 
undergoing renal biopsies. Therefore, in the current study the prevalence of celiac disease 
autoimmunity could be even higher if all patients with diabetic nephropathy would have been 
included.  
It is notable that patients having celiac disease autoimmunity were found to have more severe 
kidney disease defined by the significantly higher levels of creatinine and lower eGFR among this 
patient group. Creatinine values were higher already at the time of kidney biopsy but also after the 
follow-up period. However, renal diseases were not found to proceed more rapidly among IgA 
nephropathy patients with celiac disease autoimmunity than those without it. Furthermore, there was 
a trend showing a higher number of deaths among IgA nephropathy patients with celiac disease 
autoimmunity, but probably due to relatively short follow-up period and small study group size we 
could not show any statistically significant differences in final outcomes. The clinical course of IgA 
nephropathy is variable. Estimates of renal survival are often biased because of differences in renal 
biopsy indications in different centers [24]. In a previous Finnish material, progressive course was 
observed in 18% of IgA nephropathy patients during a median follow-up time of 10 years [25]. Hence 
a median follow-up period of 5-7 years might be too short to show the clinical worsening of the 
disease.  
Biological mechanisms underlying the positive association between celiac disease autoimmunity 
and more severe kidney disease have yet to be established. Increased intestinal mucosal permeability 
has been described in IgA nephropathy as well as in advanced chronic kidney diseases in general 
[26,27]. A defective intestinal mucosal barrier may allow increased absorption of dietary antigens 
and bacterial toxins. This may lead to activation of mucosal immune system and antigen access to the 
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systemic circulation [26-30]. Elevated levels of circulating endotoxin have been associated with more 
severe renal impairment, systemic inflammation, oxidative stress and markers of cardiac injury as 
well as reduced survival [31]. Small bowel mucosal inflammation and increased permeability are 
characteristic hallmarks of celiac disease. It could be hypothesized that co-existent celiac disease in 
patients having renal diseases may lead to more leaky intestinal mucosal barrier and therefore 
predispose to amplified systemic inflammation and more advanced kidney disease.  
We have previously reported that despite normal morphology, ongoing inflammation and stress 
are present in the small bowel of patients with IgA nephropathy [32,33]. We found increased number 
of T cells, increased expression of epithelial HLA-DR antigen and GroEL stress protein [32] as well 
as increased mucosal cyclooxygenase 2 (COX-2) expression [33] in IgA nephropathy. Our findings 
also suggested that subepithelial fibroblasts are involved in gut the mucosal inflammatory process in 
IgA nephropathy [33]. These results support the association between the gut and IgA nephropathy.  
There are many important strengths in this study. The renal biopsies and serum samples were 
collected prospectively. The study was conducted in one center where the biopsy indications, 
clinicians and pathologists were same during the whole recruitment period. Hence the data on kidney 
biopsies was uniform. On the other hand, the follow-up data of this study was retrospective. We were 
able to study the clinical outcome and prognosis of patients having IgA nephropathy and celiac 
disease autoimmunity, however, the other specific subgroups of kidney diseases were too small to 
investigate these issues. In this study we wanted to focus on the immunologic reactivity and celiac 
disease autoimmunity, not only on the biopsy-proven celiac disease, and hence the small bowel 
biopsy was not conducted to patients having positive tTGA levels. This kind of approach has also 
been applied in recent epidemiological studies where celiac disease autoimmunity defined by tTGA-
positivity has been linked to clinical outcomes and prognosis of celiac disease [34,35]. Even if we 
applied highly sensitive and specific tTGA-test in this study, it is possible that some cases with low 
positive antibody values might not express celiac disease autoimmunity. In some occasions these 
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antibodies can also be found in patients without celiac disease but having other conditions such as 
chronic liver disease or autoimmune disorders [36]. However, tTGA positivity with normal small 
bowel villous morphology may not always be a false positive finding, but a sign of early developing 
celiac disease [37], and thus tTGA positivity may represent earlier stage of the disease with less 
impact on small intestine. Additional endomysial antibody (EmA) testing and small bowel biopsies 
might have given some further information on small bowel morphology. However, both EmA- and 
endoscopic testing have their own limitations (e.g. human variation in EmA and biopsy interpretation, 
endoscopic sample cutoff differences, and testing is labor-intensive) [2]. In this study we applied 
more objective ELISA-based testing on disease process, and we focused on sero-epidemiology 
related to celiac disease autoimmunity and not only on celiac disease and enteropathy per se. 
Antibodies to gliadin were not measured due to lower specificity than tTGA [38]. Causes of deaths 
could not be extracted from the patient records, and in this study we did not have access to National 
Statistics death register. Still, as absolute number of deaths remained low in the study cohorts, we 
would not be able to draw any firm conclusions about individual causes of deaths. Furthermore, we 
had no possibility to evaluate the effect of gluten-free diet on the progression of renal diseases. 
Interestingly, IgA nephropathy has been reported to improve on a low-antigenic diet lacking gluten 
[13,14]. Besides, one previously conducted study with mice showed a beneficial impact of gluten-
free diet for the renal function [39]. For showing the influence of gluten-free diet on clinical IgA 
nephropathy, a large randomised study is urgently needed.  
To conclude, the prevalence of celiac disease autoimmunity is increased in patients undergoing 
kidney biopsy. Such autoimmunity may stay undiagnosed. The link between IgA nephropathy and 
celiac disease needs to be remembered.  Celiac disease may be associated with worse clinical outcome 
of the renal disease and therefore the co-existence of celiac disease should be taken into consideration 
when treating patients with renal diseases. The current guidelines, which do not suggest screening of 
celiac disease among patients with renal problems, may not be valid anymore according to this study. 
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More studies with longer follow-up are needed to evaluate the connections between celiac disease 
and renal diseases. 
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Table 1  
Indications for kidney biopsies in patients with and without celiac disease autoimmunity.  
Indications for kidney biopsiesa Patients with celiac disease 
autoimmunity 
n=45 
 Patients without celiac disease 
autoimmunity 
n=782 
 n %  n % 
Focal nephritic syndrome 13 29  140 18 
Renal failure 11 24  190 24 
Diffuse nephritic syndrome 9 20  171 22 
Nephrotic syndrome 8 18  116 15 
Proteinuria 4 9  117 15 
Hematuria 0 0  34 4 
Other causes 0 0  14 2 
aDifference between patients with and without celiac disease autoimmunity was not significant  
 
 
Table 2 
Renal disease according to kidney biopsy finding in patients with and without celiac disease 
autoimmunity. 
Renal disease according to 
kidney biopsya 
Patients with celiac disease 
autoimmunity 
n=45 
 Patients without celiac disease 
autoimmunity 
n=767b 
 n %  n % 
Glomerular diseases 34 76  543 71 
Tubulointerstitial diseases 4 9  107 14 
Vascular diseases 2 4  17 2 
Other 5 11  100 13 
aDifference between patients with and without celiac disease autoimmunity was not significant  
bIn 15 patients classification of renal disease was unsuccessful due to insufficient biopsy material 
 
 
 
 
 
Table 3  
Clinical data in 147 patients suffering from IgA nephropathy with and without celiac disease 
autoimmunity. 
 Patients with celiac 
disease autoimmunity 
n=12 
Patients without celiac 
disease autoimmunity  
n=135 
     P-
value 
At time of the kidney biopsy      
 Age, median (range), years 57  (21-79) 44  (17-80) 0.181 
 Female, (%) 3  (25) 45  (33) 0.751 
 BMIb, median (range), kg/m2 28  (25-36) 27  (16-47) 0.436 
 P-Creatininec, median 
(range), μmol/l 
114 (78-472) 93 (19-1541) 0.042 
 
 eGFR a, c, median (range), 
ml/min/1.73 m2 
76 (19-117) 93  (28-138) 0.048 
 Urinary protein excretion 
rated, median (range), g/day 
1.6  (0.2-4.6) 1.2  (0.07-12.9) 0.684 
 Hematuriae, n (%) 
    Negative 
    Positive 
 
1 
11 
 
(8) 
(92) 
 
23 
101  
 
(19) 
(81) 
0.692 
      
At the latest follow-up      
 Duration of follow-up, 
median (range), months 
58 (2-126) 76  (0-180) 0.782 
 
 P-Creatitinef, median (range), 
μmol/l 
156  (69-1286) 96  (43-1013) 0.059 
 
 
 
BMI= body mass index, eGFR=estimated glomerular filtration rate  
aeGFR was calculated by CKD-EPI equation  
Variables were available from the following numbers of subjects: b68, c138, d109, e136, f143, g45, 
h89 
 
 
 eGFR a, f, median (range), 
ml/min/1.73 m2 
54  (21-104) 90 (10-137) 0.022 
 
 Annual change of eGFRf, 
ml/min/1.73 m2 per year 
-1 (-13-34) -1  (-189-64) 0.750 
 Urinary protein excretion 
rateg, median (range), g/day 
0.2  (0-0.9) 0.5  (0-4.5) 0.472 
 Hematuriah, n (%) 
    Negative 
    Positive 
 
6  
3  
 
(67) 
(33) 
 
56  
24  
 
(70) 
(30) 
1.000 
 Outcome 
    Dialysis after biopsy, n (%) 
    Transplantation, n (%) 
    Died, n (%) 
 
1  
0 
3 
 
(8) 
(0) 
(25) 
 
12 
8 
13 
 
(9) 
(6) 
(10) 
 
1.000 
1.000 
0.126 
